Sebaceous Tumors of the Skin: A Study of 145 Lesions From 136 Patients Correlating Pathologic Features and DNA Mismatch Repair Staining Pattern.
Adenoma
/ metabolism
Adolescent
Adult
Aged
Aged, 80 and over
Carcinoma
/ metabolism
DNA Mismatch Repair
DNA-Binding Proteins
/ metabolism
Extremities
Face
Female
Head and Neck Neoplasms
/ metabolism
Humans
Immunohistochemistry
Male
Middle Aged
Mismatch Repair Endonuclease PMS2
/ metabolism
MutL Protein Homolog 1
/ metabolism
MutS Homolog 2 Protein
/ metabolism
Scalp
Sebaceous Gland Neoplasms
/ metabolism
Torso
Young Adult
Journal
The American Journal of dermatopathology
ISSN: 1533-0311
Titre abrégé: Am J Dermatopathol
Pays: United States
ID NLM: 7911005
Informations de publication
Date de publication:
01 Mar 2021
01 Mar 2021
Historique:
pubmed:
18
11
2020
medline:
26
10
2021
entrez:
17
11
2020
Statut:
ppublish
Résumé
Sebaceous neoplasms occur sporadically or in the setting of Muir-Torre syndrome. The data regarding the correlation of pathologic features and DNA mismatch repair (MMR) staining pattern in sebaceous tumors of the skin are very scanty and based on relatively small series of patients. The goal of this study was to correlate MMR staining pattern with selected morphological features in a series of 145 sebaceous neoplasms (sebaceous adenoma, sebaceoma, and extraocular sebaceous carcinoma) from 136 patients. Cystic change, intratumoral mucin deposits, squamous metaplasia in the absence of keratoacanthoma-like changes, ulceration, intratumoral and peritumoral lymphocytes (in cases without epidermal ulceration), and intertumoral heterogeneity proved to be significantly associated with MMR deficiency. Identification of any of these changes, alone or in combination, should prompt further investigation of the patient to exclude Muir-Torre Syndrome. Our study also confirms the previously published observation that the diagnosis and tumor location are significantly associated with MMR deficiency.
Identifiants
pubmed: 33201015
pii: 00000372-202103000-00002
doi: 10.1097/DAD.0000000000001691
doi:
Substances chimiques
DNA-Binding Proteins
0
G-T mismatch-binding protein
0
MLH1 protein, human
0
PMS2 protein, human
EC 3.6.1.-
MSH2 protein, human
EC 3.6.1.3
Mismatch Repair Endonuclease PMS2
EC 3.6.1.3
MutL Protein Homolog 1
EC 3.6.1.3
MutS Homolog 2 Protein
EC 3.6.1.3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
174-181Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Rutten A, Burgdorf W, Hugel H, et al. Cystic sebaceous tumors as marker lesions for the Muir-Torre syndrome: a histopathologic and molecular genetic study. Am J Dermatopathol. 1999;21:405–413.
Schwartz RA, Torre DP. The Muir-Torre syndrome: a 25-year retrospect. J Am Acad Dermatol. 1995;33:90–104.
Orta L, Klimstra DS, Qin J, et al. Towards identification of hereditary DNA mismatch repair deficiency: sebaceous neoplasm warrants routine immunohistochemical screening regardless of patient's age or other clinical characteristics. Am J Surg Pathol. 2009;33:934–944.
Burgdorf WH, Pitha J, Fahmy A. Muir-Torre syndrome. Histologic spectrum of sebaceous proliferations. Am J Dermatopathol. 1986;8:202–208.
Fahmy A, Burgdorf WH, Schosser RH, et al. Muir-Torre syndrome: report of a case and reevaluation of the dermatopathologic features. Cancer. 1982;49:1898–1903.
Kazakov DV, Michal M, Kacerovska D, et al. Cutaneous Adnexal Tumors. Philadelphia, PA: Lippincott Williams & Wilkins; 2012.
Singh RS, Grayson W, Redston M, et al. Site and tumor type predicts DNA mismatch repair status in cutaneous sebaceous neoplasia. Am J Surg Pathol. 2008;32:936–942.
Broekaert SM, Flux K, Kyrpychova L, et al. Squared-off nuclei and “applique” pattern as a histopathological clue to periocular sebaceous carcinoma: a clinicopathological study of 50 neoplasms from 46 patients. Am J Dermatopathol. 2017;39:275–278.
Wiedemeyer K, Kyrpychova L, Isikci OT, et al. Sebaceous neoplasms with rippled, labyrinthine/sinusoidal, petaloid, and carcinoid-like patterns: a study of 57 cases validating their occurrence as a morphological spectrum and showing No significant association with muir-torre syndrome or DNA mismatch repair protein deficiency. Am J Dermatopathol. 2018;40:479–485.
Kazakov DV, Kutzner H, Rutten A, et al. Carcinoid-like pattern in sebaceous neoplasms: another distinctive, previously unrecognized pattern in extraocular sebaceous carcinoma and sebaceoma. Am J Dermatopathol. 2005;27:195–203.
Kacerovska D, Drlik L, Slezakova L, et al. Cutaneous sebaceous lesions in a patient with MUTYH-associated polyposis mimicking muir-torre syndrome. Am J Dermatopathol. 2016;38:915–923.
Kazakov DV, Kutzner H, Spagnolo DV, et al. Discordant architectural and cytological features in cutaneous sebaceous neoplasms-a classification dilemma: report of 5 cases. Am J Dermatopathol. 2009;31:31–36.
Kazakov DV, Calonje E, Zelger B, et al. Sebaceous carcinoma arising in nevus sebaceus of Jadassohn: a clinicopathological study of five cases. Am J Dermatopathol. 2007;29:242–248.
Abbott JJ, Hernandez-Rios P, Amirkhan RH, et al. Cystic sebaceous neoplasms in Muir-Torre syndrome. Arch Pathol Lab Med. 2003;127:614–617.
Bourlond F, Velter C, Cribier B. Clinicopathological study of 47 cases of sebaceoma. Ann Dermatol Venereol. 2016;143:814–824.
Curry ML, Eng W, Lund K, et al. Muir-Torre syndrome: role of the dermatopathologist in diagnosis. Am J Dermatopathol. 2004;26:217–221.
Kruse R, Rutten A, Hosseiny-Malayeri HR, et al. Second hit in sebaceous tumors from Muir-Torre patients with germline mutations in MSH2: allele loss is not the preferred mode of inactivation. J Invest Dermatol. 2001;116:463–465.
Kruse R, Rutten A, Lamberti C, et al. Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria. Am J Hum Genet. 1998;63:63–70.
Misago N, Narisawa Y. Sebaceous neoplasms in Muir-Torre syndrome. Am J Dermatopathol. 2000;22:155–161.
Roberts ME, Riegert-Johnson DL, Thomas BC, et al. Screening for Muir-Torre syndrome using mismatch repair protein immunohistochemistry of sebaceous neoplasms. J Genet Couns. 2013;22:393–405.
Everett JN, Raymond VM, Dandapani M, et al. Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm. JAMA Dermatol. 2014;150:1315–1321.
Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26:5783–5788.
Gudgeon JM, Williams JL, Burt RW, et al. Lynch syndrome screening implementation: business analysis by a healthcare system. Am J Manag Care. 2011;17:e288–300.
Castillejo A, Vargas G, Castillejo MI, et al. Prevalence of germline MUTYH mutations among Lynch-like syndrome patients. Eur J Cancer. 2014;50:2241–2250.
Rodriguez-Soler M, Perez-Carbonell L, Guarinos C, et al. Risk of cancer in cases of suspected lynch syndrome without germline mutation. Gastroenterology. 2013,144:926–932 e921; quiz e913-924.
Perez-Carbonell L, Ruiz-Ponte C, Guarinos C, et al. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Gut. 2012;61:865–872.